4-[2-(benzyloxy)ethyl]benzyl bromide | 666844-66-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[2-(benzyloxy)ethyl]benzyl bromide
• 英文别名: 1-(2-(Benzyloxy)ethyl)-4-(bromomethyl)benzene；1-(bromomethyl)-4-(2-phenylmethoxyethyl)benzene
• CAS: 666844-66-2
• 化学式: C₁₆H₁₇BrO
• 分子量: 305.214
• InChiKey: FXLWXTKUPZPKHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Yonekubo Shigeru

  公开号：US20090074738A1

  公开（公告）日：2009-03-19

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等的药物。该化合物是一种1-取代-3-(β-D-葡萄糖苷基)氮杂环化合物，其通式表示为(I)，其前药，或其药学上可接受的盐，或其水合物或溶剂化物；包含该化合物的SGLT抑制剂；包含该化合物的制药组合物和药物组合制剂。在该式中，A代表烷基或烯烃基；B代表单键，—O—，—S—或—NH—；C代表可选择取代的芳基或杂芳基；Q独立地表示氢原子或取代基结合的碳原子或氮原子。
• 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813611A1

  公开（公告）日：2007-08-01

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, -O-, -S- or -NH-; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有 SGLT1 和/或 SGLT2 抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖症等的药物。它是由通式（I）代表的1-取代-3-（β-D-吡喃糖基）含氮杂环化合物、其原药或其药学上可接受的盐，或其水合物或溶液；含有相同物质的SGLT抑制剂；含有相同物质的药物组合物以及它们的组合药剂。式中，A代表烯基或烯基；B代表单键、-O-、-S-或-NH-；C代表任选取代的芳基或杂芳基；Q独立地代表氢原子或取代基结合的碳原子或氮原子。
• 1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813611B1

  公开（公告）日：2014-10-01
• US7750145B2
  申请人：——

  公开号：US7750145B2

  公开（公告）日：2010-07-06